ArticleBlood vessels, thrombosis & hemostasis2026
Impact of anticoagulation on quality of life in patients with slow-flow vascular malformations.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Venous malformation with localized intravascular coagulopathy in children treated with sclerotherapy and LWMH.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain from slow-flow vascular malformations is common, attributed to localized intravascular coagulopathy (LIC), and has a negative impact on quality of life (QOL). The use of anticoagulation has been anecdotal. The objective of this study was to determine the impact of anticoagulation in slow-flow vascular malformations on QOL, pain, and/or laboratory markers of LIC. A multi-institutional, prospective, nonrandomized institutional review board-approved observational study enrolled patients with slow-flow vascular malformation-related pain for whom anticoagulation was prescribed. Patient assessments (history, Pediatric Quality of Life survey, laboratory data) occurred at study entry, 2 weeks, 4 weeks, and 12 weeks (optional) after starting anticoagulation. A total of 45 patients were enrolled, with a median age of 18 years (range, 5-59). The cohort consisted of 14 males (31.1%) and 31 females (68.9%). All patients were naive to anticoagulation, prescribed low-molecular-weight heparin (n = 2), rivaroxaban (n = 40), or apixaban (n = 3). Six patients (13%) were on sirolimus and 2 on daily aspirin before starting anticoagulation. Eleven patients (24%) experienced minor bleeding events, including 6 with heavy menstrual bleeding. Two patients experienced clinically relevant nonmajor bleeding leading to cessation of anticoagulation. D-dimer and pain scores decreased, and QOL survey scores increased, with all changes being statistically significant from baseline to 2 and 4 weeks. Patients with slow-flow vascular malformations had less pain and improved QOL scores and coagulation parameters when treated with anticoagulation. Nonmajor bleeding occurred, especially menorrhagia, in ∼24% of patients, demonstrating the need to monitor and balance risks against benefits.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.